Biofrontera Stock Earnings Reports

Biofrontera reported a strong Q1 2026 driven by the first full quarter under its October 2025 strategic transaction that transferred full U.S. ownership of Ameluz and RhodoLED to the company. Product revenues were $10.1M, up ~17% year-over-year driven by ~16% unit volume growth and a price increase. Gross margin expanded to ~80% (vs. ~62% prior year) due to the new earnout structure, and cash used in operations was essentially break-even at $70k (vs. $4.1M used in Q1 2025). Adjusted EBITDA improved to negative $3.6M from negative $4.4M. Key commercial indicators: Ameluz unit shipments rose to ~29,000 tubes and installed lamp base grew to ~773 lamps across 709 offices. Clinical and regulatory progress: FDA accepted the sNDA for superficial basal cell carcinoma with a PDUFA date of Sept 28, 2026; positive Phase III results for actinic keratosis on extremities/neck/trunk supporting a planned sNDA in Q3 2026; Phase II acne data supportive of moving toward Phase III discussions with FDA in H2 2026. Corporate items: regained Nasdaq minimum bid compliance; monitoring potential tariff impacts on European imports. The company remains focused on achieving cash-flow breakeven through revenue growth, realization of a $1M milestone from a prior divestiture, disciplined expense management, and potential additional financing if needed.